UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P8‐58: Association between proton‐pump inhibitors and the ABCG2 C421A polymorphism and plasma concentration of gefitinib

Respirology (Carlton, Vic.), 2021-11, Vol.26 (S3), p.310-310

2021

Volltextzugriff (PDF)

A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis

Cancer letters, 2021-11, Vol.520, p.321-331

2021

Volltextzugriff (PDF)

P8‐169: Comparison of the efficacy of gefitinib and afatinib in pulmonary adenocarcinoma therapy with positive EGFR mutations in Javanese race

Respirology (Carlton, Vic.), 2021-11, Vol.26 (S3), p.354-354

2021

Volltextzugriff (PDF)

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Investigational new drugs, 2021-04, Vol.39 (2), p.477-487

2021

Volltextzugriff (PDF)

Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy

Carbohydrate polymers, 2024-11, Vol.344, p.122521, Article 122521

2024

Volltextzugriff (PDF)

Enhancing breast cancer treatment: Comprehensive study of gefitinib-loaded poloxamer 407/TPGS mixed micelles through design, development, in-silico modelling, In-Vitro testing, and Ex-Vivo characterization

International journal of pharmaceutics, 2024-05, Vol.657, p.124109-124109, Article 124109

2024

Volltextzugriff (PDF)

OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer

Cellular and molecular life sciences : CMLS, 2023-09, Vol.80 (9), p.272-272, Article 272

2023

Volltextzugriff (PDF)

Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

Oncology reports, 2018-12, Vol.40 (6), p.3438-3446

2018

Volltextzugriff (PDF)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

The New England journal of medicine, 2020-01, Vol.382 (1), p.41-50

2020

Volltextzugriff (PDF)

FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop

Life sciences (1973), 2021-12, Vol.287, p.120012, Article 120012

2021

Volltextzugriff (PDF)

Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases

European journal of clinical pharmacology, 2020-10, Vol.76 (10), p.1427-1436

2020

Volltextzugriff (PDF)

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

British journal of cancer, 2021-01, Vol.124 (2), p.383-390

2021

Volltextzugriff (PDF)

Design of Experiments (DoE) Approach to Optimize the Sustained Release Microparticles of Gefitinib

Current drug delivery, 2019-01, Vol.16 (4), p.364-374

2019

Volltextzugriff (PDF)

Fabrication and characterization of gefitinib-releasing polyurethane foam as a coating for drug-eluting stent in the treatment of bronchotracheal cancer

International journal of pharmaceutics, 2018-09, Vol.548 (2), p.803-811

2018

Volltextzugriff (PDF)

Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC

Drug resistance updates, 2023-09, Vol.70, p.100987-100987, Article 100987

2023

Volltextzugriff (PDF)

TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway

Oncology reports, 2023-05, Vol.49 (5), p.1, Article 84

2023

Volltextzugriff (PDF)

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

BMC cancer, 2023-08, Vol.23 (1), p.732-732, Article 732

2023

Volltextzugriff (PDF)

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma

BMC cancer, 2023-03, Vol.23 (1), p.266-266, Article 266

2023

Volltextzugriff (PDF)

EGFR activation limits the response of liver cancer to lenvatinib

Nature (London), 2021-07, Vol.595 (7869), p.730-734

2021

Volltextzugriff (PDF)

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Journal of clinical oncology, 2021-03, Vol.39 (7), p.713-722

2021

Volltextzugriff (PDF)

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

European journal of cancer (1990), 2020-01, Vol.125, p.49-57

2020

Volltextzugriff (PDF)

Regulating the physical and chemical properties of gefitinib and its positional isomer through salt formation

Journal of molecular structure, 2025-02, Vol.1322, p.140328, Article 140328

2025

Volltextzugriff (PDF)

Inhibition of miR‐578 through SOCS2‐dependent manner reverses gefitinib resistance in NSCLC cells

Environmental toxicology, 2024-03, Vol.39 (3), p.1283-1293

2024

Volltextzugriff (PDF)

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Cochrane database of systematic reviews, 2021-03, Vol.3 (3), p.CD010383

2021

Volltextzugriff (PDF)

Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer

Pharmacological research, 2021-03, Vol.165, p.105442-105442, Article 105442

2021

Volltextzugriff (PDF)

1 – 25 von 5.136

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.562)
Mit Volltextzugriff
(4.577)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Gefitinib
(4.700)
Science & Technology
(4.152)
Life Sciences & Biomedicine
(3.825)
Humans
(3.259)
Oncology
(2.339)
Lung Cancer
(1.765)
Lung Neoplasms - Drug Therapy
(1.708)
Mutation
(1.436)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(1.405)
Female
(1.363)
Male
(1.138)
Tumors
(1.020)
Quinazolines - Therapeutic Use
(1.018)
Cell Line, Tumor
(1.008)
Lung Neoplasms - Genetics
(1.005)
Epidermal Growth Factor
(997)
Antineoplastic Agents - Therapeutic Use
(995)
Kinases
(970)
Middle Aged
(960)
Epidermal Growth Factor Receptors
(912)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(3.414)
EZB Free E-Journals
(2.960)
Ingenta
(2.652)
Journals@Ovid Ovid Full Text
(1.684)
IngentaConnect Journals
(1.531)
Elsevier ScienceDirect Journals Complete
(850)
SpringerLink_现刊
(674)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(612)
NUS Single-Journal Subscriptions
(580)
Wiley Online Library Journals Frontfile Complete
(561)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(379)
Nature_系列刊
(328)
Taylor & Francis Journals
(320)
Wiley Online Library Full Collection 2018
(280)
Nexis Uni
(262)
Taylor & Francis Current Content Access
(241)
Taylor & Francis Online
(170)
SAGE Complete
(91)
Oxford University Press Journals Current
(61)
Oxford Journals 2020 Medicine
(49)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(200)
Plos One
(136)
Journal Of Thoracic Oncology
(108)
Anticancer Research
(79)
British Journal Of Cancer
(76)
Clinical Cancer Research
(74)
Clinical Lung Cancer
(68)
Scientific Reports
(68)
Cancer Chemotherapy And Pharmacology
(65)
Oncotargets And Therapy
(60)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

P8‐58: Association between proton‐pump inhibitors and the ABCG2 C421A polymorphism and plasma concentration of gefitinib

A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis

P8‐169: Comparison of the efficacy of gefitinib and afatinib in pulmonary adenocarcinoma therapy with positive EGFR mutations in Javanese race

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy

Enhancing breast cancer treatment: Comprehensive study of gefitinib-loaded poloxamer 407/TPGS mixed micelles through design, development, in-silico modelling, In-Vitro testing, and Ex-Vivo characterization

OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer

Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop

Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Design of Experiments (DoE) Approach to Optimize the Sustained Release Microparticles of Gefitinib

Fabrication and characterization of gefitinib-releasing polyurethane foam as a coating for drug-eluting stent in the treatment of bronchotracheal cancer

Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC

TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma

EGFR activation limits the response of liver cancer to lenvatinib

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer

Regulating the physical and chemical properties of gefitinib and its positional isomer through salt formation

Inhibition of miR‐578 through SOCS2‐dependent manner reverses gefitinib resistance in NSCLC cells

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer

Aktive Filter

Suchergebnisse filtern